-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company's subsidiary Suzhou Shengdia Biomedical Co., Ltd. received approval from the State Drug Administration to issue a “Pharmaceutical Clinical Trial Approval Notice” on SHR-8925 for injectable use, and will conduct clinical trials in the near future.

Zhitongcaijing·11/13/2026 08:49:05
Listen to the news
Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company's subsidiary Suzhou Shengdia Biomedical Co., Ltd. received approval from the State Drug Administration to issue a “Pharmaceutical Clinical Trial Approval Notice” on SHR-8925 for injectable use, and will conduct clinical trials in the near future.